Journal Article

DKFZ-2026-01197

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png KRAS and BRAF mutations modify adjuvant chemotherapy outcomes in early stage colorectal cancer.

Wankhede, D. (First author)DKFZ* ; Rodriguez, M. J. U.DKFZ* ; Edelmann, D.DKFZ* ; Kloor, M. ; Bläker, H. ; Brobeil, A. ; Roth, W. ; Brenner, H.DKFZ* ; Hoffmeister, M. (Last author)DKFZ*

2026
Springer Nature [London]

Abstract: KRAS and BRAFV600E mutations are established biomarkers in metastatic colorectal cancer (CRC), but their predictive roles in early-stage disease remain uncertain. We aimed to determine whether KRAS and BRAFV600E mutations modify the association between adjuvant chemotherapy regimen and survival in stage III and high-risk stage II CRC. We analyzed patients who underwent curative resection and molecular profiling for KRAS and BRAFV600E. Adjuvant chemotherapy was classified as fluoropyrimidine monotherapy (5FU) or oxaliplatin-based therapy (Ox+). Propensity score overlap weighting addressed non-randomized treatment allocation. Weighted Cox models assessed recurrence-free survival (RFS) and overall survival (OS), including tests for treatment-by-mutation interaction. Among treated patients (n = 853), a global interaction test indicated a differential association between regimens and survival by mutation status (OS, p = 0.007; RFS p = 0.049). Ox+ was associated with improved survival in patients with KRAS-mutated tumors (OS HR = 0.68, 95% CI, 0.47-0.98), and a less favorable outcome in BRAF-mutated tumors (OS HR = 2.58, 95% CI, 1.16-5.77) compared with 5FU. Outcomes were similar between Ox+ and 5FU in double wild-type (KRAS and BRAF wild-type) tumors (OS HR = 1.11, 95% CI, 0.82-1.50). These findings suggest molecular heterogeneity in treatment associations that may inform adjuvant therapy selection.

Note: #EA:C070#LA:C070#

---

Contributing Institute(s):

1. Klinische Epidemiologie der Krebsfrüherkennung (C070)
2. Biostatistik (C060)
3. Koordinierungsstelle der Cancer Prevention GS (M320)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2026

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---